Sanofi wins FDA nod for injectable multiple myeloma therapy

Sanofi (SNY) wins FDA approval for Sarclisa Escena, a subcutaneously-delivered version of its multiple myeloma therapy ...

US FDA approves Sanofi's wearable injector form of blood cancer drug

July 10 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering ...
Fierce Pharma

Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector

Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...
MPR

Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
The American Journal of Managed Care

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Approval covers all current IV isatuximab indications and introduces the first oncology product labeled for both OBI and manual SC administration. IRAKLIA (NCT05405166) established noninferiority of ...
Cure Today

FDA Approves Sarclisa Escena as a New Under the Skin Treatment Option for Multiple Myeloma

Regulatory clearance adds a 1,400-mg subcutaneous CD38 antibody option using CirCLIQ on-body delivery or provider-administered injection, maintaining the same active medicine as the IV formulation.
Targeted Oncology

FDA Approves Subcutaneous Isatuximab for Multiple Myeloma

Subcutaneous isatuximab is now approved with pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/lenalidomide/dexamethasone, aligning SC ...